A new consensus paper undertaking a complex and thorough investigation into current clinical practice has been released by an international group including many members of EuroPMP.
As pseudomyxoma peritonei (PMP) is such a rare disease, it is difficult to find large, randomised trials on which to base treatment decisions. Therefore, using the Delphi consensus model, the Peritoneal Surface Oncology Group International (PSOGI) Executive Committe, which includes may members of EuroPMP, have examined and recommended a new and current best practice for the diagnosis and treatment of PMP. The Delphi decision model was used in conjunction with a broad literature review to come to this agreement, which will now form a global best practice advisory notice.
A copy of this clinical practice guideline may be accessed here.